GENE NETWORK SCIENCES NAMES THOMAS NEYARAPALLY AS VICE PRESIDENT OF CORPORATE STRATEGY AND INTELLECTUAL PROPERTY
| Contact: |  |
Debbie Pfeifer Gene Network Sciences (206) 282-5098 debbie@gnsbiotech.com |
CAMBRIDGE, Mass., Dec. 6, 2006 – Gene Network Sciences (GNS), a leader in biosimulation, today announced that Thomas Neyarapally has joined the company as vice president of corporate strategy and intellectual property. In this newly created role, he will spearhead and implement the strategic vision for the expansion, protection and monetization of the company’s intellectual property.
Prior to GNS, Neyarapally served as an associate in the New York office of the intellectual property firm Frommer, Lawrence & Haug LLP. At FLH, he specialized in life sciences and provided counsel to multiple pharmaceutical and biotech companies. His responsibilities included: negotiating licensing, M&A and private equity agreements; creating patent non-infringement positions; resolving patent infringement cases; and advising on commercial disputes and trade secret issues. Neyarapally previously was a corporate associate at Chadbourne & Parke, LLP. Prior to Chadbourne & Parke, Neyarapally held the position of analyst at Arthur D. Little, where he focused on the pharmaceutical and chemical industries.
Neyarapally holds a J.D. and an M.B.A. from Cornell University. While attending Cornell’s Johnson Graduate School of Management, he served as a partner at BR Ventures, the only student-run venture capital firm in the United States. The fund’s first investment, which took place during Neyarapally’s tenure, was in GNS. Neyarapally graduated from the University of Connecticut with a B.S. in chemical engineering.
“Tom brings strong, relevant IP and corporate transaction experience to GNS. As our technology platform continues to expand, it is critical to protect and leverage our discoveries,” said Colin Hill, CEO of Gene Network Sciences. “We first met Tom years ago when he was a partner at BR Ventures, and are excited to have him back as a member of the team.”About Gene Network Sciences
Founded in 2000, Gene Network Sciences (www.gnsbiotech.com) is a privately held biosimulation company with offices in Cambridge, Massachusetts, and Ithaca, New York. GNS technology rapidly turns complex and heterogeneous data sets into cell and organ-level computer models able to simulate the clinical performance of drugs and drug candidates. By discovering how and why specific drug candidates impact human biology, GNS technology increases the confidence in moving drug candidates forward and ultimately improves clinical trial success rates.